We assessed tecovirimat Nail Powder treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat.Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.
0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other).Future public health emergency responses must prioritize institutional Wireless Chargers and structural racism mitigation.